BRIEF — Aquestive Therapeutics Announces FDA Acceptance Of Anaphylm™ NDA Resubmission And PDUFA Goal Date Of March 16, 2027

Oct 15 (Reuters) — Aquestive Therapeutics, Inc.: Aquestive Therapeutics Announces Fda Acceptance Of Anaphylm™ Nda Resubmission And Pdufa Goal Date Of March 16, 2027 Aquestive Therapeutics - Pdufa Goal Action Date For Anaphylm Set For March 16, 2027 Aquestive Therapeutics - Canadian New Drug Submission For Anaphylm Planned For Q4 2026 Source text:... Further company coverage: AQST.O (Reuters.Briefs@thomsonreuters.com;)